Sandoz Recalls Aprepitant Capsules and Lidocaine and Prilocaine Cream Prescription Drugs Due to Failure to Meet Child Resistant Packaging Requirement; Risk of Poisoning

What was recalled

In early March 2023, the U.S. Consumer Product Safety Commission (CPSC) announced a significant recall involving prescription medications distributed by Sandoz, a major pharmaceutical manufacturer. This action was taken because the company identified that certain batches of these critical drugs were packaged in a manner that did not comply with federal safety standards for child-resistant containers. The recall specifically targets two distinct types of prescription products: Aprepitant capsules and Lidocaine and Prilocaine cream. While these medications are essential for managing nausea associated with chemotherapy or for providing local anesthesia before minor medical procedures, their packaging failure poses a serious public health concern that requires immediate attention from patients and healthcare providers alike.

The first product affected by this recall is Aprepitant 125 mg capsules. These capsules are typically prescribed to prevent nausea and vomiting in patients undergoing cancer treatment. The specific units involved in the recall come in cartons containing one blister card with six capsules each. The packaging for these cartsons prominently displays the "Sandoz" brand name, the medication name, dosage, National Drug Code (NDC) number 0781-2323-68 for the carton and 0781-2323-06 for the blister pack, along with lot numbers and expiration dates. Notably, the packaging includes warnings stating "This unit-dose packaging is not child-resistant" and "For institutional use only," indicating that these specific packages were intended for hospital or clinical settings rather than direct-to-consumer home pharmacy dispensing.

The second product included in this recall is Lidocaine and Prilocaine 2.5%/2.5% cream, sold in 5-gram tubes. This topical anesthetic is often used to numb the skin before needle sticks or minor surgeries. The recalled units are found in cartons containing either five tubes alone or five tubes accompanied by twelve dressings. The NDC numbers for these products are 0168-0357-56 for cartons with dressings, 0168-0357-55 for cartons of just the tubes, and 0168-0357-05 for individual tubes. The packaging bears the "fougera" brand name and carries warnings marked "FOR HOSPITAL USE ONLY." Consumers need to carefully check the lot numbers on these products against the specific batches identified in the recall notice, as multiple lot numbers were affected, including LA2782, LA2784, LV0667, LX5350, MA1640, MB3205, LA2785, LR9041, and MB3209, with expiration dates ranging from February 2023 to April 2024.

It is important to understand that this recall was not due to a defect in the medication itself, but rather a failure in the packaging design. The Poison Prevention Packaging Act (PPPA) requires that prescription drugs posing a risk of poisoning to young children be packaged in special containers that are difficult for children under five years old to open. Because these specific Sandoz products were packaged without this required child-resistant feature, they have been pulled from the market to prevent accidental ingestion by curious toddlers who might find them accessible around the home.

The hazard, explained

At the heart of this recall is a simple but critical failure in packaging design: the containers for these specific prescription medications do not meet federal standards for child-resistant closures. Under the Poison Prevention Packaging Act (PPPA), most prescription drugs are legally required to be sealed in special packages that are difficult for children under five years old to open, yet manageable for adults. The products involved in this Sandoz recall—Aprepitant 125 mg capsules and Lidocaine and Prilocaine cream—were packaged in standard cartons, blisters, and tubes with continuous thread closures that lack these mandatory safety mechanisms. This means that the physical barrier intended to protect vulnerable populations is essentially absent, leaving the medication completely accessible to anyone who can reach it.

The danger lies not just in the existence of the drug, but in its accessibility. Children are naturally curious and explore their environment by putting objects in their mouths. Because the packaging does not require significant force or dexterity to open, a young child can easily remove the capsules or squeeze out the cream. Once ingested or absorbed through the skin, these substances can cause severe health issues. Aprepitant is an antiemetic drug typically used to prevent nausea and vomiting associated with chemotherapy. While effective for adults when dosed correctly, there is no established safe dosage for young children, and accidental ingestion can lead to serious toxicity or poisoning effects that are unpredictable and potentially life-threatening.

Similarly, the Lidocaine and Prilocaine cream contains two potent local anesthetics. In an adult, these are applied in controlled amounts to numb specific areas of skin for minor procedures. For a child, however, even a small amount can be dangerous. Accidental ingestion can cause central nervous system effects, including seizures, while absorption through the skin or mucous membranes can lead to heart rhythm disturbances or respiratory depression. The risk is compounded by the fact that these products were specifically labeled "For institutional use only" or "For hospital use only." In a clinical setting, staff are trained to handle hazardous materials and secure medications immediately. However, when these packages enter the general consumer market or home environments without proper oversight, that layer of professional protection disappears.

The mechanism of harm is straightforward: the packaging fails to delay access long enough for an adult to notice a child’s attempt, and it does not prevent entry entirely. This creates a window of opportunity where a child can consume a significant quantity of medication before anyone realizes there is a problem. Because children metabolize drugs differently than adults, even small amounts of these potent compounds can result in rapid onset of poisoning symptoms. This is why the recall emphasizes immediate securement; the physical design of the package currently allows for a direct pathway from shelf to stomach or skin, bypassing all standard safety checks.

Who is most at risk

When we talk about medication safety, the danger often lies not in the drug itself, but in how easily it can be accessed by those who should never take it. In this specific recall involving Sandoz’s Aprepitant capsules and Lidocaine/Prilocaine cream, the primary group at immediate risk is young children. These products were packaged without the mandatory child-resistant closures required by the Poison Prevention Packaging Act (PPPA). For a toddler or a curious preschooler, a standard screw-top cap or a simple blister pack offers almost no barrier to entry. Children are naturally exploratory and may mistake colorful or familiar-looking packaging for candy or toys. Because these specific items were labeled “For institutional use only” or “FOR HOSPITAL USE ONLY,” they were likely distributed to healthcare facilities rather than retail pharmacies, which might lead caregivers to assume the packaging was sufficiently secure for professional handling. However, once these medications leave a controlled clinical setting and enter a home environment—whether through a family member working in healthcare or a patient taking them home—the lack of child-resistant features becomes a critical vulnerability.

The physiological impact on children is particularly severe because their bodies process toxins differently than adults. Even small amounts of Aprepitant, an anti-nausea medication, can lead to serious poisoning symptoms such as drowsiness, vomiting, or respiratory distress in young ones. Similarly, the Lidocaine and Prilocaine cream contains local anesthetics that are highly potent. In children, topical absorption rates are higher due to thinner skin, meaning that even a small amount of cream ingested or absorbed through mucous membranes can cause systemic toxicity. This can result in heart rhythm abnormalities, seizures, or central nervous system depression. The risk is compounded by the fact that these products were packed in cartons and tubes that did not scream “danger” to a child’s eye, relying instead on warnings intended for adult healthcare providers.

While children are the most vulnerable demographic, elderly individuals or those with cognitive impairments also face heightened risks in this scenario. Older adults may have diminished eyesight or dexterity, making it harder to read small print or manipulate standard packaging. If a caregiver is managing medications for someone with dementia or memory loss, the absence of clear, robust child-proofing features means that accidental ingestion is more likely. The warnings printed on the carton and tube—such as “This unit-dose packaging is not child-resistant”—are easy to overlook in a busy household or clinical setting. Therefore, anyone responsible for storing these medications outside of a secure hospital pharmacy must treat them with extreme caution, assuming that any household member, regardless of age or cognitive ability, could accidentally access and consume the contents.

How to tell if you have the recalled item

Identifying whether your prescription medications are part of this specific recall requires a careful check of both the outer carton and the inner packaging or container. Because the issue stems from the type of packaging rather than the medication itself, you might not immediately notice anything unusual unless you know exactly where to look. The primary red flag for these products is their intended use. Both the Aprepitant capsules and the Lidocaine and Prilocaine cream involved in this recall were manufactured specifically for institutional settings, such as hospitals or clinics, rather than for direct retail sale to individual consumers. Therefore, if you received these medications directly from a pharmacy counter in a standard child-resistant container, they are likely not part of this batch. However, if you are managing care for someone who has been discharged with these supplies, or if you are a caregiver handling hospital-provided medications at home, you need to inspect the labels closely.

For the Aprepitant 125 mg capsules, start by looking at the outer box. The brand name "Sandoz" should be clearly printed on the carton, along with the medication name and dosage. Crucially, check the warning text on the side or back of the box. If you see the phrase "This unit-dose packaging is not child-resistant" followed by "For institutional use only," this product is part of the recall. Inside the carton, you will find a blister card containing six capsules. This blister card itself is also non-child resistant and lacks the typical push-through safety features found in standard home prescriptions. You should verify the National Drug Code (NDC) number on the carton. The recalled NDC for this specific configuration is 0781-2323-68 for the full carton or 0781-2323-06 for the blister pack alone. Additionally, check the lot numbers printed on the packaging. If your box displays lot numbers LK3209, LC6454, or expiration dates of April 2024 or December 2023, it is definitely included in this recall.

If you have the Lidocaine and Prilocaine cream, the identification process involves checking both the tube and the carton. This product comes in 5-gram tubes with a distinctive white closure cap that uses continuous threading. The name "fougera®" is printed on the tube, along with the medication dosage of 2.5%/2.5%. Look at the outer carton for the warning "FOR HOSPITAL USE ONLY," which distinguishes these units from standard retail versions. The NDC numbers to look for are 0168-0357-56 (for cartons with 5 tubes and 12 dressings) or 0168-0357-55 (for cartons with just 5 tubes). The individual tube NDC is 0168-0357-05. Lot numbers for the cream include LA2782, LA2784, LV0667, LX5350, MA1640, MB3205, LA2785, LR9041, and MB3209. Expiration dates for these creams range from March 2023 to April 2024. If your packaging matches any of these NDCs, lot numbers, or expiration windows, you have a recalled item that requires immediate attention.

What to do — step by step

Your refund, repair, or replacement options

When you encounter a recall involving prescription medications like the ones affected in this Sandoz safety notice, it is natural to wonder about the financial and logistical implications. The good news is that the remedy provided by the manufacturer is designed to be both straightforward and cost-free for you. In this specific instance, the company has not issued a standard refund or offered a replacement bottle of the medication itself. Instead, the core of the solution focuses on immediate safety through the provision of specialized protective packaging. Sandoz is offering a free child-resistant pouch specifically intended to store the recalled products safely. This approach addresses the root cause of the recall—the failure of the original packaging to meet federal child-resistance standards—without disrupting your ongoing medical treatment.

The process for obtaining this safety aid is designed to be accessible. You do not need to send back the medication or wait for a complex approval process. Your primary action is to contact Sandoz directly using the resources they have established for this recall. You can reach their dedicated support team by calling their toll-free number at 866-300-2207. The customer service representatives are available to assist you from 8 a.m. to 5 p.m. Eastern Time, Monday through Friday. This direct line is the most efficient way to initiate the process and receive clear instructions tailored to your specific lot numbers and product types.

If you prefer digital communication or need to review additional details before speaking with an agent, Sandoz provides alternative contact methods. You may send an email inquiry to Sandoz6768@sedgwick.com for written correspondence regarding the recall. Additionally, comprehensive information about this notice is available online. You can visit the Sandoz patient resources page at https://www.us.sandoz.com/patients-customers/product-safety-notices, or navigate to www.us.sandoz.com and select the "Product Safety Notices" link located below the main carousel on their homepage. These online resources serve as a central hub for all recall-related documentation and updates.

It is important to understand why the remedy is limited to a pouch rather than a product replacement or refund. The recall stems from a packaging compliance issue under the Poison Prevention Packaging Act, not from a defect in the drug’s efficacy or chemical composition. Therefore, once you have secured the child-resistant pouch from Sandoz and placed your medication inside it, you are permitted to continue using the drugs exactly as prescribed by your healthcare provider. The remedy is structured to eliminate the poisoning risk while allowing you to maintain your treatment plan without interruption or additional expense. There is no charge for this pouch, and no requirement to return the original product to receive it.

What can happen if you ignore it

It is completely understandable to feel hesitant about disrupting your medication routine. When a recall notice lands in your inbox or on your doorstep, the immediate reaction is often one of fatigue rather than fear. You might think that since you have been using the product for weeks or months without issue, ignoring the warning until you can get to a pharmacy or call the toll-free number is a minor inconvenience. However, with this specific recall involving Sandoz’s Aprepitant capsules and Lidocaine and Prilocaine cream, treating the packaging defect as a mere administrative nuisance rather than a critical safety barrier carries significant, potentially life-altering risks.

The core issue here is not that the medication itself has gone bad or become toxic. The drugs are chemically stable and effective. The danger lies entirely in the accessibility of these potent substances to those who should never ingest them: young children. Because the packaging lacks the child-resistant features mandated by the Poison Prevention Packaging Act, a toddler can open the carton or tube with minimal effort. Aprepitant is an anti-nausea medication often prescribed for cancer patients undergoing chemotherapy, while Lidocaine and Prilocaine is a local anesthetic used to numb skin before procedures. Both are powerful pharmaceutical agents that interact with the body’s nervous system in profound ways.

If a child swallows even a small amount of these medications because they were left in non-child-resistant packaging, the consequences can be severe. For Aprepitant, accidental ingestion can lead to serious central nervous system effects, including drowsiness, agitation, and potentially more complex neurological symptoms depending on the dose relative to the child’s body weight. With Lidocaine and Prilocaine cream, the risks are equally grave. These anesthetics work by blocking nerve signals; if absorbed in significant quantities through a child’s digestive system or mucous membranes, they can cause methemoglobinemia—a condition where the blood’s ability to carry oxygen is reduced—or cardiac arrhythmias (irregular heartbeats). In extreme cases, overdose of local anesthetics can lead to seizures, respiratory depression, and death.

While the recall notice states that no incidents have been reported at this time, it is crucial to recognize that a lack of reported injuries does not mean the risk is low; it means we have been lucky so far. Accidental poisonings often happen in split seconds—in the blink of an eye when a curious child finds an unsecured box or tube left on a counter or nightstand. By continuing to use these products without securing them in the provided child-resistant pouch, you are leaving your child vulnerable to a random accident that could result in permanent health damage or tragedy. The "institutional use only" and "hospital use only" labels found on the cartons indicate that this packaging was designed for controlled environments where staff manage dispensing, not for homes where children roam freely. Ignoring this distinction turns a safe medical tool into a hidden hazard.

Furthermore, consider the emotional and logistical toll of an accident. If a child were to ingest these medications, the outcome would likely involve emergency room visits, hospitalization, and long-term monitoring. This creates immense stress for families who are already dealing with serious health conditions that require these prescriptions. The remedy offered by Sandoz is simple: secure the medication immediately in the free pouch provided. There is no need to throw away the medicine or stop your treatment prematurely. You can continue to use the medication exactly as directed once it is safely stored. Choosing to ignore the recall forces you to gamble with a child’s safety for the sake of temporary convenience, a trade-off that no parent or caregiver should ever make.

Staying safe: broader tips

When dealing with prescription medications, particularly those that carry a risk of severe poisoning if ingested by children, the primary defense is proactive environmental management rather than reactive measures. While this recall highlights a specific packaging failure, the underlying principle applies to all households with young children or cognitively impaired individuals: storage location and method are just as critical as the medication itself. The Poison Prevention Packaging Act exists because standard containers can sometimes be opened by determined toddlers or elderly individuals who lack the hand strength for child-resistant caps but not the wisdom to avoid them. Therefore, relying solely on the container’s label is a mistake. Always store medications in high, locked cabinets or drawers that are completely out of sight and reach. Visibility is a powerful trigger for curiosity; if a child cannot see a pill bottle or cream tube, they are significantly less likely to attempt to retrieve it.

It is also vital to understand the difference between "child-resistant" and "child-proof." No packaging is truly child-proof against a determined toddler, which is why secondary containment methods, such as the free pouches offered in this recall, serve as an essential backup layer of security. For general safety, consider using lockable medicine boxes or safes for all potent medications, not just those with known packaging defects. Additionally, never refer to medicine as "candy" to encourage compliance, and always keep medications in their original containers with the original labels intact. Transferring pills into unlabeled daily organizers is a common practice for convenience, but it removes critical identification information in an emergency and may strip away any remaining child-resistant features.

Beyond physical storage, maintaining awareness of product safety recalls is a simple yet powerful habit that protects your entire family. Set up alerts on your smartphone or subscribe to email notifications from the Consumer Product Safety Commission (CPSC), the Food and Drug Administration (FDA), and your local pharmacy. These agencies often issue urgent communications regarding defects that may not be immediately obvious, such as chemical leaching, mechanical failures, or packaging errors like the one affecting these Sandoz products. Regularly reviewing the "Recalls" section of their official websites can help you identify issues before they result in harm.

Finally, cultivate an open line of communication with your pharmacist and healthcare provider. They are your best resource for understanding the specific risks associated with any new prescription. Ask questions about proper storage, disposal of unused medications, and what to do if accidental ingestion occurs. By combining secure storage practices with active monitoring of safety alerts, you create a robust defense system that goes far beyond any single product’s packaging limitations.